產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白與其它公司提供的重組蛋白不同，rHup16-INK4a-TAT蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白
| Synonyms | CDK4I, MTS-1, p16INK4A |
| Species | Human |
| Source | Escherichia coli. |
| Molecular Weight | Approximately18.0 kDa, a single non-glycosylated polypeptide chain containing 167 amino acids. |
| Quantity | 5μg/25μg/1000μg |
| AA Sequence | 重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGYGRK KRRQRRR |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Data is not available. |
| Physical Appearance | 重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.0. |
| Endotoxin | Less than 1 EU/μg of rHuP16-INK4a-TAT as determined by LAL method. |
| Reconstitution | 重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人細(xì)胞周期蛋白依賴性激酶抑制劑2A，同種型1-TAT蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Buda G, Maggini V, Galimberti S, et al. 2007. Leuk Res, 31: 569-70. 2. Komiya A, Suzuki H, Aida S, et al. 1995. Jpn J Cancer Res, 86: 622-5. 3. Jares P, Fernandez PL, Nadal A, et al. 1997. Oncogene, 15: 1445-53. 4. Mori T, Miura K, Aoki T, et al. 1994. Cancer Res, 54: 3396-7. |
| Background | Cyclin-dependent kinase inhibitors (CDKIs) are proteins that bind to and inhibit the activity of CDKs. Two major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds to and inhibits the activities of CDK4 and CDK6. The p21 family (p21, p27, p28 and p57) can bind to broad range of CDK-cyclin complexes and inhibit their activities. CDKIs are capable of suppressing growth, and several lines of evidence strongly suggest that at least some CDKIs may be tumor suppressor proteins. p16-INK4A is the member of p16 family and is encoded by CDKN2A gene in humans. It has three isoforms, which are wildly expressed but not detected in brain or skeletal muscle, except that isoform 3 is pancreas-specific. Defects in p16INK4A are a cause of Li-Fraumeni syndrome (LFS) and melanoma-astrocytoma syndrome (MASTS). The TAT transduction peptide can help rHuP16-INK4a with acrossing all kind of biomembranes in vivo and has no effect on the super structure of the protein. |
